Agilent Technologies, Inc.

New York Stock Exchange
Back to all articles
Bullish +60

Bullish Move: Sue Rataj Shows Confidence, Acquires $241K In Agilent Technologies Stock

📊 On March 23, Agilent Technologies director Sue Rataj purchased $241,156 worth of stock via a SEC Form 4 filing.

📈 This transaction involved acquiring 2,158 shares at a total value of approximately $241K in a single trade.

📉 Agilent shares gained 0.89% during Tuesday's morning session, trading around $112.21 per share.

📉 Revenue grew 6.96% year-over-year as of January 31, 2026, though this trailed Health Care sector peers.

💵 Gross margin remains strong at 52.61%, highlighting the company's superior cost efficiency and profitability.

📉 Earnings per share dropped to $1.08, which is lower than the industry average for the sector.

🛡️ The company maintains a low debt-to-equity ratio of 0.49, indicating a sound financial structure below industry norms.

💰 Market capitalization is positioned above industry benchmarks, reflecting a strong market presence and size.

📉 The P/E ratio stands at 24.73, which is lower than the industry average suggesting a discounted valuation.

📈 Conversely, the P/S ratio of 4.51 exceeds industry norms, indicating potential overvaluation based on sales performance.

🏭 Agilent operates in life science and diagnostics with revenue from three main segments: life science, cross lab operations, and applied end markets.

🌍 Over half of sales are generated from biopharmaceutical, chemical, and advanced materials end markets globally.

⚖️ The EV/EBITDA ratio is 18.23, presenting a potential value opportunity as it is lower than industry averages.

📜 Insider transactions like Rataj's purchase signal optimism and positive anticipation for future stock performance.

🔍 SEC Form 4 filings must be completed within two business days of a transaction by company insiders.

🏢 Agilent was originally spun out of Hewlett-Packard in 1999 and has grown into a leading measurement technology firm.

🌐 Operations are geographically diverse, with significant concentrations in the US and China.

⚠️ This article is generated by Benzinga's automated content engine and reviewed by an editor for publication.

Bullish Signals
  • Director Sue Rataj executed a significant insider buy on March 23, purchasing 2,158 shares for $241,156, signaling strong confidence in Agilent Technologies' future prospects.
  • Agilent Technologies achieved a remarkable 6.96% revenue growth rate over the last three months as of January 31, 2026, demonstrating substantial top-line earnings expansion.
  • The company maintains an impressive gross margin of 52.61%, indicating superior cost efficiency and profitability compared to industry peers.
  • Agilent's debt-to-equity ratio stands at a healthy 0.49, below industry norms, highlighting a sound financial structure with strong solvency.
  • The stock is currently trading up 0.89% in the morning session at $112.21, reflecting positive market sentiment.
  • With a P/E ratio of 24.73 lower than the industry average, Agilent Technologies presents an attractive discounted valuation for investors.
  • The company's EV/EBITDA ratio of 18.23 is below industry benchmarks, suggesting a potential value opportunity where investors pay less for earnings power.
Risk Factors
  • Agilent Technologies' revenue growth rate of 6.96% trails behind its industry peers in the Health Care sector.
  • Earnings per Share (EPS) declined and currently sits at $1.08, falling below the industry average.
  • The Price to Sales (P/S) ratio is elevated at 4.51, reflecting a valuation above industry norms and potential overvaluation based on sales performance.
  • The company relies heavily on biopharmaceutical, chemical, and advanced materials end markets which account for over half of its sales, creating concentration risk.
Full Analysis
On March 23, Sue Rataj, Director at Agilent Technologies (NYSE: A), executed a significant insider buy of 2,158 shares worth $241,156, as disclosed in a Form 4 filing with the U.S. Securities and Exchange Commission. This purchase occurred while Agilent's stock was trading up 0.89% at $112.21 during Tuesday's morning session, suggesting a bullish signal from a key company official. The insider transaction is being framed as an indicator of optimism regarding the stock's future performance, though analysts note that insider transactions should be evaluated alongside broader financial metrics rather than in isolation. Agilent Technologies has demonstrated strong financial fundamentals as of January 31, 2026, reporting a revenue growth rate of 6.96% and an impressive gross margin of 52.61%, which highlights superior cost efficiency compared to industry peers. However, the company's earnings per share currently stand at $1.08, which is below the industry average, while its debt-to-equity ratio remains robust at 0.49, indicating a sound financial structure with leverage significantly lower than industry norms. The market capitalization is noted as being above industry benchmarks, reflecting a strong market presence and established scale within the sector. Valuation analysis presents a mixed picture for Agilent Technologies, with a price-to-earnings (P/E) ratio of 24.73 trading lower than the industry average, suggesting a discounted valuation that could represent a buying opportunity. Conversely, the company's price-to-sales (P/S) ratio is elevated at 4.51 compared to industry norms, indicating a higher valuation relative to sales performance. The enterprise value-to-EBITDA ratio stands at 18.23, which is below industry averages and reinforces the argument that investors are paying less for each unit of earnings before interest, taxes, depreciation, and amortization. Originating from Hewlett-Packard in 1999, the firm now operates through three segments serving life science, diagnostics, and applied end markets, with over half of its sales derived from biopharmaceutical and chemical sectors where customer retention is considered particularly strong.